BioCentury | Oct 2, 2020

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Scripps mAb shows signs of COVID-19 protection in hamsters

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A team led by Scripps Research Institute researchers has identified an anti-spike mAb that could treat COVID-19. High throughput screening of 2,045 antibodies derived from eight donors, who previously...
BioCentury | Jul 3, 2020

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

With a $41.5 million series A round led by Rick Klausner, Arch and Foresite, Bit Bio is moving beyond commercializing a handful a cell types to the moonshot goal of generating every cell type in...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

Inovio looks to be the second company after Moderna to start a U.S. trial of a COVID-19 vaccine, kicking the study off several months ahead of its previously projected summer trial start date. Outside of...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
BioCentury | May 28, 2019
Distillery Therapeutics

Split intein-based gene therapies for two types of congenital blindness

DISEASE CATEGORY: Ophthalmic disease INDICATION: Blindness Mouse studies suggest gene therapies delivering ABCA4 or CEP290 as split inteins could help treat Stargardt disease or Leber congenital amaurosis type 10 (LCA10), respectively. The therapies consist of...
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
Items per page:
1 - 10 of 333